An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Astria Therapeutics to Present Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Astria Therapeutics, Inc. (NASDAQ:ATXS) will present a poster titled "Burdens of Disease and Treatment in Hereditary Angioedema: Interview Insights from HAE Patients" at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit. This presentation highlights insights from patients suffering from hereditary angioedema (HAE) and will be accessible to event registrants from October 18, 2021, to November 18, 2021. Astria is developing STAR-0215, a monoclonal antibody aimed at treating HAE.
Positive
None.
Negative
None.
BOSTON--(BUSINESS WIRE)--
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced it will be presenting “Burdens of Disease and Treatment in Hereditary Angioedema: Interview Insights from HAE Patients” at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit.
The poster will be available to registrants on the NORD Rare Diseases and Orphan Products Breakthrough Summit Event Platform from October 18, 2021, to November 18, 2021.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.
